Use of WEGOVY for this indication is supported by a 68-week, double-blind, placebo-controlled clinical trial in 201 pediatric patients aged 12 years and older with a BMI corresponding to 95th percentile for age and sex and from studies in adult patients with obesity [see Clinical Studies (14.3)]
Sixteen percent (16%) of WEGOVY-treated patients and 8% of placebo-treated patients, respectively, discontinued study drug due to an adverse event
The result - insured patients may still face high monthly costs, while uninsured individuals often find retail prices impossible to afford
Other research has shown conflicting results, with some studies suggesting neutral or even protective effects of GLP-1 medications on diabetic eye disease over longer follow-up periods
At Kohn Medical & Weight Loss, we can provide you with the support you need to stay on track and reach your goals
Emerging research is also exploring whether long-term use could be linked to pancreatic issues or gallbladder disease, though more studies are needed
